Merck hikes dividend 11%; Parallel trade triggers U.K. drug shortages;

 @FiercePharma: Pfizer has big plans for Prevenar in China: It's aiming to penetrate rural areas as the vax market grows-Reuters. News | Follow @FiercePharma 

> Merck ($MRK) raised its dividend by 11% to 42 cents per share in its first payout hike since 2004, sending shares up by 2% in early trading. News | Report

> Parallel trade is depleting U.K. supplies of some drugs, with 80% of surveyed pharmacists saying they couldn't fill certain prescriptions because of shortages. Story

> Generics maker Stada posted a loss for the first nine months of the year, because of write-downs on its Serbian business and heightened competition in Germany. Item

> GlaxoSmithKline ($GSK) bought back 850,000 of its shares for prices between 1367 and 1394 pence. Article

> India's Lupin will build up in Japan, planning to grow more than 14% annually in that market. News

> UCB released new positive data on its rheumatoid arthritis drug Cimzia, including a study showing that response by the 12th week of treatment would predict longer-term outcomes. Item

> Wolters Kluwer agreed to sell its pharma marketing and publishing services to Spring Science+Business Media. Story

> Belleville, NJ, said it would refund $1.7 million in property taxes on Roche Diagnostics' site, for overpayments made from 2007 to 2011. Report

> Baxter International ($BAX) said it wrapped up its $380 million acquisition of Baxa, a Colorado pharmacy technology company. Baxter release

Biotech News

 @FierceBiotech:  Sanofi drug REGN727 packs anti-cholesterol punch in Ph2 trials. News | Follow @FierceBiotech

 @JohnCFierce: Merck gets 2 CRLs, from FDA, buries them in a 62-page filing. Somebody didn't get the memo on transparency. Report | Follow @JohnCFierce

 @MaureenFierce: Cervical cancer vaccines may cut need for cancer screenings. Item | Follow @MaureenFierce

> FDA deals Merck two R&D setbacks with pair of CRLs. Item

> Sanofi drug packs anti-cholesterol punch in Ph2 trials. Report 

Vaccines News

> Nabi explores options after NicVAX flunks trial. News

> Researchers find two potential lupus vax treatments. Item

> Gates backs microneedle polio vaccine work. Article

> PANVAC for breast, ovarian cancer shows early promise. Report

> Study: Cervarix could cut need for cancer screenings. News

Manufacturing News

> Chinese pharma exec gets suspended death sentence. Story

> Genentech, INIS demonstrate art of FDA response. Report

> International Isotopes gets FDA warning. Article

> OxyContin abuse overshadows formulation fix. News

> Manufacturing embraces IT as some drugmakers minimize R&D focus. Article

> KV crows over Makena purity as FDA checks claim. Story

 And Finally... A new approach to brain monitoring finds signs of awareness in "vegetative" patients. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.